Novel production of a new oral vaccine for COVID-19 with a recombinant Bacillus subtilis strain

加拿大联邦和省政府呼吁研究机构和私营合作伙伴开发创新解决方案，以控制Covid-19病毒的传播。开发疫苗是一个主要的优先事项。一种稳定且具有成本效益的发酵工艺可能是一种解决方案。Ulysse Biotechnologies是一家加拿大企业，专注于工业微生物和生物技术在农业食品和卫生领域的应用。企业动员科研团队，开发在细菌和酵母菌株中表达SARS-Covid-19刺突蛋白受体结合域的微生物平台，以生产新型口服疫苗。其中一种菌株是枯草芽孢杆菌，它作为一种疫苗递送系统，帮助人体免疫系统识别Covid-19病毒，并产生针对该病毒的必要抗体。该菌株现在已经准备好在发酵罐中生产，该公司呼吁UQTR评估菌株的稳定性和效率，并制定一种可以提高产品产量并降低生产成本的发酵策略。然后提出了一个研究项目，以加速这种新型口服疫苗的生产，满足对疫苗的迫切需求。

The Canadian federal and provincial governments call on research institutions and private partners to develop innovative solutions to control the Covid-19 virus spread. Development of a vaccine is one major priority. A stable and cost-effective fermentation process for Covid-19 vaccine production could be a solution. Ulysse Biotechnologies is a Canadian enterprise specialist in application of industrial microorganisms and biotechnology in agrifood and hygiene sectors. The enterprise mobilizes its scientific team to develop a microbial platform for expression of SARS-Covid-19 spike (S) protein receptor binding domain in bacteria and yeast strains in order to manufacture a novel oral vaccine. One of these strains is a Bacillus subtilis that shall be used as a vaccine delivery system which helps the human immune system to recognize Covid-19 virus and produce necessary antibodies against this virus. This strain is now ready to be produced in fermenters and the company called on UQTR to assess the strain stability and efficiency and to develop a fermentation strategy that could increase the product yield and reduce the production cost. A research project is then proposed to accelerate the manufacture of this new oral vaccine and meet the urgent need for vaccine.